61 completed, 17 active not recruiting, 15 recruiting, 10 terminated. 121 Phase 2, 36 Phase 1, 1 Phase 3.
Follow Rhabdomyosarcoma: new trials by email Literature Review of Rhabdomyosarcoma trials Research Report on Rhabdomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy, Left Arm treated with vehicle serum and Intense Pulsed Light Therapy - Photodamaged Skin | Phase 2 / Phase 3 | Not yet recruiting | Goldman, Butterwick, Fitzpatrick and Groff | 20 | 2026-07-10 | 2026-07-07 |
| Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib - Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2026-03-01 | 2026-03-03 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma ATRA+VAC, ATRA+VAC+Anlotinib - Rhabdomyosarcoma | Phase 2 | Not yet recruiting | Fudan University | 106 | 2026-01-01 | 2026-01-21 |
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents pazopanib, TGI chemotherapy, CIV chemotherapy - Rhabdomyosarcoma, Recurrent, Refractory | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 38 | 2025-02-01 | 2025-02-10 |
| Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas PEEL-224, Temozolomide, Vincristine - Sarcoma, Sarcoma, Ewing | Phase 1 / Phase 2 | Recruiting | David S Shulman, MD | 63 | 2025-01-27 | 2026-02-19 |
| Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors Albumin-paclitaxel Injection - Paget Disease, Extramammary, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 100 | 2024-11-30 | 2024-12-20 |
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors PEN-866, Vincristine, Temozolomide - Sarcoma, Ewing, Rhabdomyosarcoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 64 | 2024-10-31 | 2026-03-16 |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors Silmitasertib, Irinotecan, Temozolomide - Neuroblastoma, Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 104 | 2024-10-30 | 2026-11-12 |
| Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen Pucotenlimab - Rhabdomyosarcoma, Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 82 | 2024-06-06 | 2024-06-13 |
| Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease Vincristine, Dactinomycin, Cyclophosphamide - Rhabdomyosarcoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 135 | 2024-03-13 | 2026-11-16 |
| Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study Doxorubicin Hydrochloride Liposome+Irinotecan, Temozolomide+Irinotecan+Vincristine - Rhabdomyosarcoma, Child | Phase 2 | Recruiting | Sun Yat-sen University | 88 | 2023-12-30 | 2026-05-18 |
| Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Peptide vaccine IPX - Ewing Sarcoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University Hospital Tuebingen | 30 | 2023-09-19 | 2026-05-04 |
| VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors Atezolizumab, Vincristine, Irinotecan - Solid Tumor, Rhabdomyosarcoma | Phase 1 / Phase 2 | Active not recruiting | University of Texas Southwestern Medical Center | 23 | 2023-04-18 | 2026-11-04 |
| Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children Realgar-Indigo Naturalis Formulation, Radiotherapy - Rhabdomyosarcoma, Child | Phase 2 | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 53 | 2023-01-31 | 2023-02-01 |
| A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin - Solid Tumors, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Children's National Research Institute | 2022-11-10 | 2025-01-01 |
Showing 20 of 121. Sign in to see all of them.
Sarcoma (68) · Sarcoma, Ewing (55) · Osteosarcoma (53) · Neuroblastoma (46) · Neuroectodermal Tumors, Primitive, Peripheral (29) · Wilms Tumor (25) · Medulloblastoma (24) · Sarcoma, Synovial (24) · Liposarcoma (22) · Leiomyosarcoma (21) · Ependymoma (20) · Hepatoblastoma (20) · Rhabdoid Tumor (20) · Fibrosarcoma (19)
Neoplasms by Histologic Type (121) · Neoplasms, Muscle Tissue (121) · Myosarcoma (120) · Neoplasms, Connective and Soft Tissue (119) · Neoplasms (112) · Neoplasms, Connective Tissue (91) · Neoplasms, Nerve Tissue (77) · Neoplasms, Bone Tissue (72) · Neoplasms, Glandular and Epithelial (64) · Neoplasms, Germ Cell and Embryonal (62) · Neuroectodermal Tumors (61) · Neoplasms, Neuroepithelial (57) · Neoplasms by Site (54) · Neuroectodermal Tumors, Primitive (53) · Sarcoma (53)
Temozolomide (15) · Vincristine (15) · Irinotecan (13) · Cyclophosphamide (12) · Doxorubicin (7) · Filgrastim (7) · Dactinomycin (6) · Etoposide (6) · Ifosfamide (6) · Magnetic Resonance Spectroscopy (6) · Gemcitabine (5) · Phantoms, Imaging (5) · Specimen Handling (5) · Vinorelbine (5) · X-Rays (5)
National Cancer Institute (NCI) (31) · European Organisation for Research and Treatment of Cancer - EORTC (7) · St. Jude Children's Research Hospital (6) · Memorial Sloan Kettering Cancer Center (5) · Children's Oncology Group (4) · Eisai Inc. (3) · Eli Lilly and Company (3) · Fudan University (3) · Brown University (2) · Children's National Research Institute (2) · City of Hope Medical Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Novartis Pharmaceuticals (2) · Sarcoma Alliance for Research through Collaboration (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)
United States (89) · Canada (19) · Puerto Rico (15) · Australia (14) · France (14) · Germany (11) · Spain (10) · Italy (9) · United Kingdom (9) · Belgium (8) · Netherlands (8) · China (6) · Denmark (5) · Switzerland (5) · New Zealand (4)
Robert Maki, MD, PhD (3) · AeRang Kim, MD, PhD (2) · Christine M Heske, M.D. (2) · Hongxia Wang, Doctor (2) · AeRang Kim (1) · Alberto Pappo, MD (1) · Alberto S. Pappo, MD (1) · Alok Kothari, M.D. (1) · Andrea T Franson (1) · Antonio Casado (1) · Arhanti Sadanand, MD (1) · Axel Le Cesne, MD (1)
PMID 31401903, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17264331, PMID 17336054, PMID 18676758, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20471824, PMID 21896345, PMID 22682017, PMID 23382028, PMID 24215845, PMID 28950372, PMID 29216400, PMID 29567632, PMID 29669701, PMID 30410720, PMID 31013172, PMID 31513481, PMID 31575518, PMID 31987969, PMID 32192573, PMID 32554315, PMID 32701199, PMID 33305087, PMID 33591402, PMID 34004576, PMID 34343032, PMID 34392187, PMID 34486544, PMID 35353553, PMID 35483358, PMID 37178647, PMID 37398992, PMID 38815151, PMID 38873934, PMID 38935895, PMID 39298716, PMID 40313040, PMID 40937822
U10CA180886 (15), U10CA098543 (6), P30CA008748 (2), P30CA033572 (2), UM1CA097452 (2), UM1CA228823 (2), 2014 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), N01CM62203 (1), N01CM62206 (1), P01CA225618 (1)